Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 19

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 19
---
 25% 50% 75% 100% 125% 150% 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 STAAR U.S. ICL Units YoY Growth U.S. Refractive Market YoY Growth 1. Source: Wells Fargo Research Note, April 21, 2025. 2. Source: STAAR Q1 2025 Earnings Call, May 7, 2025. 3. Source: STAAR Q2 2024 Earnings Call, August 7, 2024. 4. Source: STAAR Investor Presentation, September 26, 2025. 5. Source: STAAR Q4 2024 Earnings Call, February 11, 2025. 2 B

Broadwood Partners, L.P. Share of U.S. Refractive Vision Corrective Procedures 1 … And Are Expected to Continue to Take Market Share 27 ICLs are growing in popularity in the U.S., seemingly at the expense of other refractive procedures ▪ Data regarding laser vision correction indicates overall procedure volumes are dropping, while ICL procedure volumes are increasing 2 ▪ We believe, as management does, that the benefits of STAAR’s EVO ICL procedure will make it the preferred choice for refractive vision correction over time ▪ Benefits of EVO ICL include no permanent alteration to the structure of the eye, a quick, less - invasive procedure, flexibility for future procedures as patients age and need replacements, UV protection, and avoidance of dry eye syndrome 2 ▪ ICL is already the procedure of choice in markets like Japan, where surgeon confidence is high, patients have a greater awareness of ICL as an alternative to laser vision correction, there is a negative bias against LASIK, and the market environment is favorable 2 ▪ STAAR has only just begun to tap into the large U.S. market, and we believe the Company is poised to extend EVO ICL's position as the standard for lens - based refractive vision correction 1. Source: Wells Fargo Research Note, April 21, 2025. 2. Source: STAAR Q1 2025 Earnings Call, May 7, 2025. 62% 18% 12% 8%